182 assets in Multiple Sclerosis

Therapeutic assets addressing Multiple Sclerosis, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Cladribine Multiple Sclerosis	University Hospital, Strasbourg, France	P4	BBB (72)
Fampridine Multiple Sclerosis	MGH Institute of Health Professions	P4	BBB (72)
Nabiximols Multiple Sclerosis	Jazz Pharmaceuticals	P4	BBB (72)
Ocrelizumab Multiple Sclerosis	Polpharma Biologics International AG	P4	BBB (72)
Teriflunomide Multiple Sclerosis	Sanofi	P4	BBB (72)
Fingolimod Multiple Sclerosis	Biogen	P4	BB (70)
Interferon ?1 (Human Fibroblast Protein Moiety) Multiple Sclerosis	Bayer	P4	BB (70)
Natalizumab Multiple Sclerosis	Biogen	P4	BB (70)
2-BUTENEDIOIC ACID, (2E)-, DIMETHYL ESTER Multiple Sclerosis	Biogen	P4	BB (67)
Glatiramer Multiple Sclerosis	Centre Hospitalier Universitaire de Nice	P4	BB (67)
Rituximab Multiple Sclerosis	Rennes University Hospital	P4	BB (67)
4-((1E)-2-(6-(2-)2-(2-FLUOROETHOXY)ETHOXY)ETHOXY)PYRIDIN-3-YL)ETHENYL)-N-METHYLBENZENAMINE Multiple Sclerosis	Brain Health Alliance	P4	BB (66)
Divozilimab Multiple Sclerosis	Biocad	P3	BB (66)
Methotrexate Multiple Sclerosis	National Institute of Allergy and Infectious Diseases (NIAID)	P4	BB (66)
Ozanimod Multiple Sclerosis	The University of Texas at Dallas	P4	BB (66)
Alemtuzumab Multiple Sclerosis	Queen Mary University of London	P4	BB (65)
Peginterferon Beta-1A Multiple Sclerosis	Bayer	P4	BB (65)
Humax-Cd20 Multiple Sclerosis	University Hospital, Lille	P4	BB (64)
Monomethyl Fumarate Multiple Sclerosis	Biogen	P3	BB (64)
PBR28 Multiple Sclerosis	Massachusetts General Hospital	P4	B (63)
Prednisone Multiple Sclerosis	Holy Name Medical Center, Inc.	P4	B (63)
Tetanus Toxoid Multiple Sclerosis	Celgene	P4	B (63)
Modafinil Multiple Sclerosis	Clinical Academic Center (2CA-Braga)	P4	B (62)
Ponesimod Multiple Sclerosis	Biogen	P3	B (62)
Amantadine Multiple Sclerosis	Hospital San Carlos, Madrid	P3	B (60)
Cetirizine Multiple Sclerosis	University of Miami	P4	B (60)
Clemastin Multiple Sclerosis	University of California, San Francisco	P3	B (60)
Cyclophosphamide Multiple Sclerosis	Indapta Therapeutics, INC.	P3	B (60)
Naltrexone Multiple Sclerosis	Truway Health, Inc.	P3	B (60)
Pittsburgh Compound B Unlabelled Multiple Sclerosis	Yale University	P2	B (60)
Cholestyramine Multiple Sclerosis	Sanofi	P3	B (59)
Interferon Beta Multiple Sclerosis	Biogen	P3	B (59)
Ppsv23 Multiple Sclerosis	Celgene	P3	B (59)
(±)-2-(O-Chlorophenyl)-2-(Methylamino)Cyclohexanone Multiple Sclerosis	Alta Bates Summit Medical Center	P2	B (58)
Ferumoxytol Multiple Sclerosis	Sanofi	P3	B (58)
Nivestim Multiple Sclerosis	S. Andrea Hospital	P2/3	B (58)
Temelimab Multiple Sclerosis	GeNeuro Innovation SAS	P2	B (58)
Biib091 Multiple Sclerosis	Biogen	P2	B (57)
Drf Multiple Sclerosis	Biogen	P2	B (57)
Fludarabine Multiple Sclerosis	Indapta Therapeutics, INC.	P2	B (57)
Fludeoxyglucose Multiple Sclerosis	Brigham and Women's Hospital	P4	B (56)
Frexalimab Multiple Sclerosis	Sanofi	P3	B (56)
Human Faecal Matter Multiple Sclerosis	London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's	P2	B (56)
Silodosin Multiple Sclerosis	Atlantic Health System	P4	B (56)
Testosterone Enantate Multiple Sclerosis	Tulane University	P4	B (56)
Vidofludimus Multiple Sclerosis	Immunic AG	P3	B (56)
Equine Atg Multiple Sclerosis	Haukeland University Hospital	P3	CCC (55)
Metformin Multiple Sclerosis	State University of New York at Buffalo	P2	CCC (55)
Midazolam Multiple Sclerosis	Johns Hopkins University	P2	CCC (55)
Oxygen Multiple Sclerosis	Jay C. Buckey Jr.	P4	CCC (55)

Showing 1 to 50 of 182 assets

PreviousPage 1 of 4Next